Posted by Michael Wonder on 20 Jul 2016
AstraZeneca receives approval in the EU for Qtern (saxagliptin and dapagliflozin) for treatment of type 2 diabetes mellitus
19 July 2016 - AstraZeneca today announced that the European Commission has approved Qtern (saxagliptin/dapagliflozin) tablets for the treatment of type 2 diabetes in all 28 EU member countries plus Iceland, Liechtenstein and Norway.
The fixed-dose combination of saxagliptin and dapagliflozin is the first DPP-4i/SGLT-2i combination product to be approved in Europe.
Qtern is indicated for adults with type 2 diabetes aged 18 years and older to improve glycaemic control when metformin and/or sulphonylurea and one of the mono-components of Qtern alone do not provide adequate control, or when a patient is already being treated with the free combination of saxagliptin and dapagliflozin.
